1.28 USD
▼-0.07-5.19%
盘后 1.56 0.00%
2026-11-20
市值
$30.47M
市盈率
—
EPS
-1.91
股息率
—
52 周区间
1.25 – 11.88
成交量
37.99K
Beta
—
目标价
16.33
52W 低 1.2552W 高 11.88
价格走势
公司简介
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeut...